Skip to main content
Premium Trial:

Request an Annual Quote

RetinalGenix Technologies Acquires DNA/GPS

NEW YORK – RetinalGenix Technologies announced on Wednesday that it acquired pharmacogenomics company DNA/GPS.

The acquisition gives Petaluma, California-based RetinalGenix the rights to DNA/GPS's platform technology, which allows healthcare workers to monitor and screen patients from their homes via retinal imaging and genetic mapping, as well as to diagnose systemic disorders such as heart disease, Alzheimer's, dementia, and Parkinson's, among others.

Retinal changes can provide early evidence of disease, enabling providers to observe correlations between retinal damage and heart problems, high blood pressure, and kidney damage.

"We believe this platform to be a breakthrough in advanced retinal imaging and genetic mapping that could become a new standard for the diagnosis of systemic disease and could replace expensive and time-consuming procedures such as CT, MRI, and PET at a much lower cost," said RetinalGenix CEO Jerry Katzman.

As part of the acquisition, RetinalGenix has also added DNA/GPS Founder Larry Perich to its advisory board.

The Scan

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.